Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of DM-101-PX compared to placebo in birch pollen allergic adults. As an secondary objectives, the trial will also assess the number of participants receiving the maximum intended DM-101PX dose and to assess the effect of treatment with DM-101PX compared with placebo on blood allergy biomarkers. Expanded access to the study treatment is not available.
Epistemonikos ID: 02e5562da836dc272ddb9fc1bd923b272b0df572
First added on: Oct 28, 2026